European Organization for Research and Treatment of Cancer (Eortc) Open Label Phase Ii Study on Glufosfamide Administered as a 60-Minute Infusion Every 3 Weeks in Recurrent Glioblastoma Multiforme
AuthID
P-000-E69
P-000-E69